Anyone with a G6PD deficiency: Glucose-6-phosphate dehydrogenase deficiency is a genetic condition that makes people prone to hemolytic anemia under oxidative stress
As we age or face health challenges, these cells can become damaged, leading to restricted circulation and increased heart disease risk
Sermorelin is one peptide on one pathway with a 10 to 12 minute half-life
Cognitive behavioral therapy Drug therapy First-line antidepressants: selective serotonin reuptake inhibitors (SSRIs) eg, fluoxetine (Prozac) and citalopram (Celexa), serotonin-norepinephrine reuptake inhibitors (SNRIs) eg, duloxetine (Cymbalta) and venlafaxine (Effexor), and atypical antidepressants eg, bupropion (Wellbutrin) and mirtazapine (Remeron) Second-line antidepressants, including: tricyclic antidepressants eg, amitriptyline (Elavil) and clomipramine (Anafranil) monoamine oxidase inhibitors (MAOIs) eg, tranylcypromine (Parnate) and phenelzine (Nardil) Atypical antipsychotics: eg, aripiprazole (Abilify) and quetiapine (Seroquel) Neurostimulation techniques Electroconvulsive therapy Vagus nerve stimulation Repetitive transcranial magnetic stimulation Ablative neurosurgery What are Some Emerging Treatments for Depressive Disorders
The only difference is the **nominal volume** and what it implies: faster diluent turnover, a limited number of septum punctures, almost no prolonged environmental exposure once opened
